Enliven Therapeutics (NASDAQ:ELVN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enliven Therapeutics (NASDAQ:ELVN) from a sell rating to a hold rating in a report published on Saturday morning.

Other equities research analysts also recently issued reports about the stock. Mizuho lifted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, HC Wainwright lifted their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.40.

Enliven Therapeutics Trading Up 1.5%

ELVN opened at $44.90 on Friday. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $48.53. The company has a market cap of $2.73 billion, a P/E ratio of -24.14 and a beta of 0.26. The company has a fifty day moving average price of $35.27 and a two-hundred day moving average price of $26.46.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, research analysts forecast that Enliven Therapeutics will post -1.7 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,230 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the sale, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. The trade was a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the sale, the insider directly owned 740,188 shares of the company’s stock, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 16,230 shares of company stock valued at $473,201 over the last three months. Corporate insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Commodore Capital LP increased its position in shares of Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after acquiring an additional 17,809 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares in the last quarter. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after purchasing an additional 418,673 shares in the last quarter. Vanguard Group Inc. grew its position in Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after purchasing an additional 142,378 shares in the last quarter. Finally, State Street Corp grew its position in Enliven Therapeutics by 9.1% in the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after purchasing an additional 87,725 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.